Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies

Nature Medicine volume 8, pages 775–777 (2002)Cite this article

Efforts to control vessel growth have focused on vascular endothelial growth factor (VEGF) and its primary receptor VEGFR-2. New data could shift that focus to other members of the VEGF family and the receptor VEGFR-1, particularly in inflammatory diseases (pages 831–840 & 841–849).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Stem-cell recruitment and mobilization in the bone marrow by PlGF, and sites of inhibition by VEGFR-1-blocking antibodies.

Renee Lucas

References

  1. Carmeliet, P. & Jain, R.K. Angiogenesis in cancer and other diseases. Nature 407, 249–257 (2000).

    Article  CAS  PubMed  Google Scholar 

  2. Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocrine Rev. 18, 4–25 (1997).

    Article  CAS  Google Scholar 

  3. Ferrara, N. & Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nature Med. 5, 1359–1364 (1999).

    Article  CAS  PubMed  Google Scholar 

  4. Epstein, S.E., Kornowski, R., Fuchs, S. & Dvorak, H.F. Angiogenesis therapy: Amidst the hype, the neglected potential for serious side effects. Circulation 104, 115–119 (2001).

    Article  CAS  PubMed  Google Scholar 

  5. Luttun, A. et al. Revascularization of ischemic tissues by PlGF treatment and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt-1 antibody. Nature Med. 8, 831–840 (2002).

    Article  CAS  PubMed  Google Scholar 

  6. Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone marrow microenviroment. Nature Med. 8, 841–849 (2002).

    Article  CAS  PubMed  Google Scholar 

  7. Gerber, H.-P. et al. VEGF regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954–958 (2002).

    Article  CAS  PubMed  Google Scholar 

  8. Eriksson, U. & Alitalo, K. Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr. Top. Microbiol. Immunol. 237, 41–57 (1999).

    CAS  PubMed  Google Scholar 

  9. Aase, K. et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104, 358–364 (2001).

    Article  CAS  PubMed  Google Scholar 

  10. Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Med. 7, 575–583 (2001).

    Article  CAS  PubMed  Google Scholar 

  11. Matsumoto, T. & Claesson-Welsh, L. VEGF receptor signal transduction. Sci. STKE 2001, RE21 (2001).

  12. Shibuya, M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Int. J. Biochem. Cell Biol. 33, 409–420 (2001).

    Article  CAS  PubMed  Google Scholar 

  13. Fong, G.H., Zhang, L., Bryce, D.M. & Peng, J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development 126, 3015–3025 (1999).

    CAS  PubMed  Google Scholar 

  14. Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis In mice. Proc. Natl. Acad. Sci. USA 95, 9349–9354 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Cho, N.K. et al. Developmental control of blood cell migration by the Drosophila VEGF pathway. Cell 108, 865–876 (2002).

    Article  CAS  PubMed  Google Scholar 

  16. Ziegler, B.L. et al. KDR receptor: A key marker defining hematopoietic stem cells. Science 285, 1553–1558 (1999).

    Article  CAS  PubMed  Google Scholar 

  17. Ziche, M. et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest. 76, 517–531 (1997).

    CAS  PubMed  Google Scholar 

  18. Bergers, G. et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biol. 2, 737–744 (2000).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ludwig Institute for Cancer Research, Stockholm Branch, Stockholm, Sweden

    Ulf Eriksson

  2. Molecular/Cancer Biology Laboratory and Ludwig Institute for Cancer Research, Haartman Institute and Biomedicum Helsinki, University of Helsinki, Finland

    Kari Alitalo

Authors
  1. Ulf Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kari Alitalo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eriksson, U., Alitalo, K. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nat Med 8, 775–777 (2002). https://doi.org/10.1038/nm0802-775

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0802-775

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing